Physicians' Academy for Cardiovascular Education

Potent P2Y12 receptor inhibitor shows stronger antithrombotic effect in T2DM patients with CVD

A randomized, cross-over study showed a stronger antiplatelet effect and a faster and more potent antithrombotic effect with ticagrelor than with clopidogrel in T2DM patients with stable CVD.

Literature - Zafar MU, Baber U, Smith DA, et al. - Thromb Haemost 2017, published online ahead of print

Main results


This randomized, cross-over trial demonstrated that treatment with ticagrelor resulted in a stronger inhibition of platelet aggregation, and more importantly, a more potent antithrombotic effect than clopidogrel in T2DM patients with stable CVD.


Show references

Find this article online at Thromb Haemost

Share this page with your colleagues and friends: